Search

  • HOME
  • Search
Letter to the Editor
1878
Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi
Clin Mol Hepatol. 2024;30(2):263-265.   Published online January 18, 2024
View: 1653   Download: 112
Review
1813
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi
Clin Mol Hepatol. 2023;29(2):242-251.   Published online March 20, 2023
View: 4279   Download: 213  Web of Science: 3  Crossref: 5
Letter to the Editor
Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
Received March 1, 2024  Accepted March 5, 2024  
DOI: https://doi.org/10.3350/cmh.2024.0157    [Epub ahead of print]
View: 681   Download: 88
Equivalent Prevalence and Progression of Chronic Kidney Disease in NAFLD and MASLD
Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
Received April 15, 2024  Accepted May 20, 2024  
View: 165   Download: 23
1 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X


Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 156
TOTAL : 1850016
Close layer